MD, PhD, MSc Pharm, Associate Professor in Experimental Clinical Pharmacology
Joachim Gullbo has a scientific background in development and evaluation of anti-cancer drugs, from the early stages of lead identification and in vitro assays, to toxicology and proof-of-concept investigations in animal models and clinical trials.
He has co-authored more than 75 scientific publications within the cancer field and has supervised two PhD students working with alkylating peptides.
Dr Gullbo has clinical specialist training in Clinical Pharmacology and Oncology and was earlier Head of Oncology at Uppsala University Hospital. He is currently Medical Monitor at Theradex Oncology, Princeton, US. Dr Gullbo is a scientific advisor to Oncopeptides.
MD, PhD, Professor of Oncology at Uppsala University Hospital and Consultant in Clinical Oncology, Uppsala University Hospital
Peter Nygren has a scientific background in cell biology and is a researcher in clinical oncology focused on gastrointestinal cancer. His research is focusing on predictive tests for anticancer drugs and new drug development.
He was Medical Head of the clinical trials unit, at the Department of Oncology, Uppsala University Hospital and was assistant scientific secretary at the Swedish Cancer Society for six years.
He has published approximately 140 scientific publications within oncology and had three years of regulatory experience, assessing new anticancer drugs at the Medical Products Agency.